Tarsus Pharmaceuticals, Inc. entered into a Securities Purchase Agreement on August 5, 2026, for an oversubscribed private placement of equity securities expected to generate approximately $125.0 million in gross proceeds. The transaction includes the sale of 2,098,519 shares of common stock at $56.00 per share and pre-funded warrants to purchase up to 133,625 additional shares at $55.9999 per warrant. The offering is led by Barclays Capital Inc., with BofA Securities and William Blair as co-placement agents, and involves participation from existing Alkeus Pharmaceuticals investors such as TCGX and Bain Capital Life Sciences alongside new Tarsus investors. Proceeds are intended to fund clinical development and commercial activities related to the pending acquisition of Alkeus Pharmaceuticals. The private placement is scheduled to close on August 7, 2026, subject to customary conditions.
